BRIEF-Edgewise Therapeutics Announces Sale Of Sevasemten To Servier For Up To $2.65 Bln

Edgewise

Edgewise

EWTX

0.00

June 1 (Reuters) - Edgewise Therapeutics Inc EWTX.O:

  • EDGEWISE THERAPEUTICS: ANNOUNCES SALE OF SEVASEMTEN TO SERVIER FOR UP TO $2.65 BILLION

  • EDGEWISE THERAPEUTICS: TO RECEIVE $1.55 BILLION IN UPFRONT CASH CONSIDERATION ELIGIBLE FOR UP TO $1.1 BILLION IN MILESTONE PAYMENTS

  • EDGEWISE THERAPEUTICS: EMPLOYEES IN MUSCULAR DYSTROPHY BUSINESS TO RECEIVE COMPARABLE OFFERS FROM SERVIER

  • EDGEWISE THERAPEUTICS: PROCEEDS EXPECTED TO FULLY FUND EDG-7500 DEVELOPMENT THROUGH POTENTIAL APPROVAL

  • EDGEWISE THERAPEUTICS: REMAINS ON TRACK TO INITIATE PHASE 2 TRIAL OF EDG-15400 IN HEART FAILURE WITH PRESERVED EJECTION FRACTION

  • EDGEWISE THERAPEUTICS: ON TRACK TO REPORT 12-WEEK CIRRUS-HCM PART D DATA IN Q2 2026

Further company coverage: EWTX.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.